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1  | INTRODUC TION
The immunological response to influenza vaccine and/or natural 
infection is evaluated by serological techniques recommended by 
regulatory authorities. The most common and widely used are the 
hemagglutination inhibition (HI) and the single radial hemolysis (SRH) 
assays, which are officially recognized by the European Medicines 
Agency (EMA).1
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Background: The immunological response to influenza vaccine and/or natural infec-
tion is evaluated by serological techniques, the most common being hemagglutina-
tion inhibition (HI), single radial hemolysis (SRH), and virus neutralization assays, 
which is commonly used in a micro- neutralization (MN) format. ELISA is not officially 
required; however, this assay is able to measure different class- specific antibodies. 
The four assays identify different sets or subsets of antibodies.
Objectives: The aim of this study was to establish the correlation among four sero-
logical assays using four seasonal influenza strains.
Methods: The HI, SRH, MN assays, and ELISA were performed on four seasonal in-
fluenza strains.
Results: A strong positive correlation was found between HI and MN and between 
SRH and MN assays for influenza A strains. The B strains also showed good correla-
tions among the three assays. A positive correlation was also found between ELISA 
and the “classical” assays for all strains. Concerning the correlates of protection, as 
defined	by	HI	≥	40	and	SRH	≥	25	mm2, good agreement was observed for the influ-
enza A strains. By contrast, the agreement for the B strains was very low.
Conclusions: There is a positive strong correlation among the four serological assays 
for both A and B strains, especially for the HI and MN assays. There is good agree-
ment on correlates of protection between HI and SRH assays for the A strains, but 
very low agreement for the B strains, suggesting higher sensitivity of SRH than HI 
assay in detecting antibodies against the influenza B viruses.
K E Y W O R D S
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The HI assay is considered the gold standard as a correlate of 
protection for influenza vaccines2-4 and has proved to be simple, 
rapid, and cost- effective. The aim of the assay is to detect antibod-
ies, capable of inhibiting the agglutination between red blood cells 
and the viral hemagglutinin (HA).5 The HI titer is expressed as the 
reciprocal of the highest serum dilution that shows complete inhibi-
tion of agglutination.6	An	antibody	titer	of	40	is	generally	regarded	
as a protective threshold level, beyond which there is less than 50% 
chance of contracting influenza infection.7
Despite its wide application, the assay has limitations, including 
low sensitivity for influenza B and avian viruses, inadequacy in the 
evaluation of live attenuated vaccines and a high degree of variabil-
ity among laboratories, due to many factors, including the source of 
reagents (such as red blood cells and receptor- destroying enzyme) 
and the lack of standardized protocols.7-9
The SRH assay is a robust technique based on the passive he-
molysis of red blood cells, which is mediated by complement and 
induced by the antibody- antigen complex. The hemolysis produces 
an easily identifiable “area of hemolysis,” which is proportional to 
the concentration of influenza antibodies, mainly IgG, present in 
serum samples.3,10,11 The advantages of the SRH assay are the small 
quantities of influenza virus and serum required, the ability to si-
multaneously analyze a large number of serum samples without 
pre- treatment (apart from complement inactivation) and unbiased 
results available after overnight incubation.12 In addition, the assay 
detects small differences in antibody levels, distinguishes differenti-
ates between closely related influenza strains, and is more sensitive 
for influenza B strains than the HI assay.12-15 A hemolysis area of 
25 mm2 or greater is generally considered to be an immunological 
correlate of protection.16
Another widely used serological technique is the virus neu-
tralization	 assay,	 which	 is	 recommended	 by	 the	 World	 Health	
Organization	 (WHO)	 for	 the	 measurement	 of	 functional	 antibod-
ies against highly pathogenic avian viruses6 and currently included 
in the EMA guidelines on influenza vaccines.1 Commonly used in a 
micro- neutralization (MN) format, this assay detects antibodies at 
low titers and distinguishes between pre- and post- vaccination ti-
ters in paired sera, especially in the case of small (less than 2- fold) 
differences in titers.17 The disadvantage lies in the handling of wild- 
type viruses, which, in the case of highly pathogenic strains, require 
high- level facilities. The assay suffers from high interlaboratory vari-
ability, owing to the lack of common reference protocols and dis-
crepancies in endpoint determination. Here, MN titer is expressed as 
the reciprocal of the serum dilution showing at least 50% inhibition 
of cytopathic effect in mammalian cell culture.7,18 To date, no cor-
relates of protection have been established for the MN assay.
In addition to the traditional immunological techniques, the 
enzyme- linked immunosorbent assay (ELISA) detects influenza anti-
bodies. Advantages are its ability to measure different class- specific 
IgM, IgA, and IgG antibodies in serum samples and nasal wash in 
response to influenza infection and/or vaccine and to use a wide 
range of antigen preparations. This assay is particularly suitable for 
large- scale serological investigations, as it yields unbiased results in 
a few hours and is cost- effective and amenable to complete automa-
tion. In addition, the ELISA assay is reproducible and reagents can be 
standardized (e.g, coating antigen, conjugate for Ig detection).7,19,20 
ELISA mainly detects anti- HA antibodies, even when the whole virus 
is used, as HA is immunodominant.21,22 ELISA can also be used to 
detect responses to other influenza antigens when purified single 
antigens are used for coating. The use of purified HA antigens or 
a recombinant fragment of the HA globular head may considerably 
improve the specificity of ELISA.7,19,23-26
The four assays identify different sets or subsets of antibodies. 
The HI assay detects antibodies that bind to the viral HA and pre-
vent the virus- red blood cells agglutination by blocking the receptor 
binding site; the MN assay identifies functional neutralizing anti-
bodies, including those that recognize epitopes in the stem region 
of HA, which are conserved among different subtypes of influenza 
A viruses.17,20,27 Consequently, the MN assay could be less specific 
in adults and elderly subjects with extensive previous exposure to 
influenza viruses.27 However, MN is more sensitive than HI, particu-
larly in detecting low- titer seroconversions. A combination of assays 
could improve the sensitivity and specificity of influenza vaccine 
evaluation.
The SRH assay may recognize antibodies not only against the 
surface glycoproteins but also those against the internal antigens, 
leading to a potential lack of specificity to antibodies against HA.3 
However, the immune response to HA is immunodominant over the 
response to other viral proteins, such as neuraminidase and internal 
proteins.21
Several studies have compared serological techniques for the 
evaluation of antibody response to influenza viruses or vaccination. 
Overall, the HI, SRH, and MN assays have shown significant pos-
itive correlations, especially for influenza A strains.11,14,27-29 A re-
cent study has revealed that the correlation between SRH and MN 
is greater than that between SRH- HI and HI- MN assays.30 ELISA 
shows good agreement between the HI and MN assays; notably, 
ELISA seems to be more sensitive than HI assay, especially in de-
tecting low levels of antibody, owing to the low background.24,31,32
Few previous studies have dealt with the correlations among the 
four assays.
The aim of this study was to establish the correlations among the 
four immunological assays: HI, SRH, MN, and ELISA using four egg- 
grown seasonal influenza strains.
2  | MATERIAL S AND METHODS
2.1 | Virus antigens
The virus antigens and infectious influenza viruses were seasonal 
influenza	strains	obtained	from	NIBSC:	A/California/7/2009	(H1N1,	
12/168-	15/252),	 A/Texas/50/2012	 (H3N2,	 13/112-	12/298),	 B/
Brisbane/60/2008	 (B,	 13/234-	15/146)	 (Victoria	 lineage),	 and	 B/
Massachusetts/02/2012	 (B,	 13/106-	14/106)	 (Yamagata	 line-
age). Live viruses were used for MN assay; inactivated antigen 
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preparations, obtained from NIBSC, were used for HI, SRH, and 
ELISA. All viruses used were egg- grown.
2.2 | Serum samples
Human	 serum	 samples	 (n	=	450)	 from	 adults	 were	 obtained	 from	
the Serum Bank of the Laboratory of Molecular Epidemiology, 
Department of Molecular and Developmental Medicine, University 
of Siena, Italy. The samples were collected anonymously and stored 
in compliance with Italian ethics law.
The only information available for each serum sample was the 
subject’s age and the year of sampling. Serum samples were ran-
domly selected from a total of 600 samples available at the Serum 
Bank and collected in the area of Siena in 2015. The selection was 
performed by means of a randomization list, the main selection cri-
terion being balanced numbers for gender and age.
Influenza sheep hyperimmune serum samples were provided 
by	NIBSC	and	were	used	as	positive	controls:	A/California/7/2009	
(H1N1,	 09/152),	 A/Texas/50/2012	 (H3N2,	 13/110),	 B/
Brisbane/60/2008 (B, 11/136), and B/Massachusetts/02/2012 (B, 
13/182).
Human serum without IgA, IgM, and IgG was used as negative 
controls	(Sigma-	Aldrich,	S5393).
2.3 | Hemagglutination inhibition assay
All serum samples, including the sheep serum samples and nega-
tive control, were pre- treated with receptor- destroying enzyme 
(RDE) (ratio 1:5) from Vibrio Cholerae (Sigma- Aldrich, Milan, Italy) 
for 18 hours at 37°C in a water bath and then heat- inactivated for 
1	hour	at	56°C	in	a	water	bath	with	8%	sodium	citrate	(ratio	1:4).
Fresh turkey red blood cells were centrifuged twice, washed with 
a	saline	solution	(0.9%),	and	adjusted	to	a	final	dilution	of	0.35%.
From an initial dilution of 1:10, serum samples were 2- fold di-
luted	in	duplicate	with	saline	solution	(0.9%)	in	a	96-	well	plate;	25	μL 
of	standardized	viral	antigen	(4	HA	units/25	μL) was added to each 
well, and the mixture was incubated at room temperature for 1 hour. 
Red blood cells were added and, after 1- hour incubation at room 
temperature, the plates were evaluated for the presence of agglu-
tination inhibition.
The antibody titer was expressed as the reciprocal highest serum 
dilution that showed complete inhibition of agglutination. As the 
starting dilution was 1:10, the lower limit of the detectable antibody 
titer	was	10.	When	the	titer	was	below	the	detectable	threshold,	the	
results were conventionally expressed as 5 for calculation purposes, 
half the lowest detection threshold.
2.4 | Single radial hemolysis assay
Before being used in the SRH assay, serum samples were heat- 
inactivated at 56°C for 30 minutes in a water bath. Fresh turkey 
red blood cells were centrifuged and washed twice with phosphate 
buffer saline (PBS). Diluted virus antigen was added to the red blood 
cell suspension at a concentration of 2000 hemagglutinin units (HAU) 
per milliliters (mL). In order to allow the adsorption of viral antigen to 
the	red	blood	cells,	the	suspension	was	incubated	at	4°C	for	20	min-
utes. A solution of chromium chloride (CrCl3) 2.5 mmol/L was added 
to the suspension and incubated at room temperature for 10 min-
utes to increase the binding affinity between the red blood cells and 
the viral antigen. The suspension was mixed once and subsequently 
centrifuged. The supernatant was removed, PBS was added, and the 
pellet was carefully re- suspended. A stock solution of 1.5% agarose- 
agarose low gelling in PBS containing 0.1% sodium azide was pre-
pared.	The	agarose	stock	solution	was	kept	at	45°C	in	a	water	bath.
Each SRH plate contained red blood cells- viral antigen suspen-
sion and guinea pig complement in the agarose mixture. The final 
suspension was vigorously shaken and then evenly spread onto each 
plate and incubated at room temperature for 30 minutes, and the 
agarose	was	 allowed	 to	 set	 at	4°C	 for	30-	90	minutes.	Holes	were	
made in each plate with a calibrated punch, and 6 microliters (μL) 
of serum samples and controls was added through each hole. The 
plates	 were	 stored	 in	 a	 humid	 box	 and	 incubated	 at	 4°C	 for	 16-	
18 hours in the dark. After overnight incubation, the plates were 
incubated	 in	a	water	bath	at	37°C	for	90	minutes,	after	which	 the	
diameters of the hemolysis areas were read in millimeters (mm) with 
a calibrated viewer.12
2.5 | Micro- neutralization assay
Madin Darby Canine Kidney (MDCK) cells were maintained for 
a maximum of 30 passages in EME medium containing 10% fetal 
bovine serum (FBS), 2 mmol/L L- glutamine, 1% non- essential amino 
acid solution, and 100 U/mL penicillin- streptomycin. The MDCK cell 
cultures were grown at 37°C in 5% CO2. Serum samples, previously 
heat- inactivated at 56°C for 30 minutes, were diluted 2- fold with 
EMEM	culture	medium	supplemented	with	0.5%	FBS	 in	a	96-	well	
plate, mixed with an equal volume of virus (100 TCID50/well), and in-
cubated for 1 hour at 37°C in 5% CO2. At the end of incubation, the 
MDCK cell suspension (1.5 × 105 cells/mL) was added to the plates, 
which were then stored in an incubator (37°C, 5% CO2) for 5 days. 
After incubation, the plates were observed by optical microscopy 
and evaluated for cytopathic effect. A cytopathic effect higher than 
50% indicates infection. The titer was expressed as the inverse of 
the last dilution that showed inhibition of cytopathic effect.
2.6 | ELISA
To evaluate humoral responses, the ELISA was performed on human 
serum	samples	in	96-	well	flat	bottom	half-	area	Microlon	titer	plates	
(Greiner, Alphen a/d Rijn, The Netherlands). Antigens used for 
ELISA coating were lyophilized SRID antigen, obtained from NIBSC 
(Potters Bar, Hertfordshire, United Kingdom). Plates were coated 
overnight	at	4°C	with	1	μg/mL hemagglutinin (50 μL/well in PBS) of 
the relevant influenza antigens.
Following blocking with 100 μL/well of 3% BSA (Sigma, 
Zwijndrecht, The Netherlands) in PBS- T, plates were washed and 
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samples were loaded. Human serum samples were loaded onto 
the plates and incubated for 1 hour at room temperature. Samples 
were tested at a starting dilution of 1:500 (H1N1, H3N2, and B/
Yamagata	lineage)	or	1:1000	(B/Victoria	lineage)	and	3-	fold	serially	
diluted over four wells. A pool of human sera diluted 2- fold over 
seven wells was used as a calibrator on every plate. After incubation, 
plates were washed and incubated for 1 hour at room temperature 
with 50 μL/well of 1:1250 diluted goat anti- human IgG conjugated 
to alkaline phosphatase (Thermo Fisher Scientific, Etten- Leur, The 
Netherlands). ELISA was developed with 50 μL/well p- nitrophenyl 
phosphate (pNPP; Fluka, Poole, UK) for 30 minutes. The opti-
cal	density	 (OD)	was	 read	at	405	nm	using	a	Bio-	Rad	plate	 reader	
(model iMark—microplate reader). ODs were converted to arbitrary 
units (AUs) using a four- parameter logistic fit (ADAMSEL, www.
F IGURE  1 Correlation between HI- MN, HI- SRH, and SRH- MN titers. Size and color indicate the number of observations at the same 
coordinates. The size of the circle is proportional to the square root of the number of observations at that position; thus, the size is directly 
proportional to the number of observations. Symbol colors also indicate the number of observations (magma color), where black indicates 
single observations and yellow indicates many observations. A, . B, . C,
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malariaresearch.eu), where 1 AU yields an OD of 1 over the back-
ground. Thus, the amount of AU of a sample is the reciprocal dilution 
at which an OD of 1 over the background is achieved.
2.7 | Statistical analysis
All statistical analyses were performed using Microsoft R- Open, 
version	3.4.3	(R	Core	Team	(2018);	R:	A	language	and	environment	
for statistical computing; R Foundation for Statistical Computing, 
Vienna, Austria. Figures were prepared using the ggplot2 pack-
age in Microsoft R- open. Correlation (Pearson product- moment 
correlation coefficient, Pearson’s r) and linear regression analy-
ses were performed on log 2 transformed data for HI, MN, and 
ELISA. SRH data were not log transformed. Kappa statistics were 
calculated using the R package fmsb (https://CRAN.R-project.org/
package=fmsb).
3  | RESULTS
The	 human	 serum	 samples	 (n	=	450)	 were	 tested	 by	 HI,	 SRH,	
MN, and ELISA assays to evaluate the assay correlation using 
F IGURE  1 Continued
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four	 seasonal	 influenza	 strains:	 A/California/7/2009	 (H1N1),	 A/
Texas/50/2012 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and 
B/Massachusetts/02/2012	(Yamagata	lineage).
For the influenza A strains, a strong positive correlation was 
found between HI and MN assays (Pearson’s r	=	0.81-	0.84),	 SRH	
and HI assays (Pearson’s r = 0.82- 0.85), and SRH and MN assays 
(Pearson’s r	=	0.69-	0.86)	(Figure	1;	Table	1).
Strong positive correlations were also found between HI and MN 
(Pearson’s r = 0.62- 0.71), SRH and HI (Pearson’s r	=	0.64-	0.75),	and	SRH	
and MN assays (Pearson’s r = 0.67- 0.71) for B/Massachusetts/02/2012 
and B/Brisbane/60/2008, respectively. Notably, correlations for the 
B/Massachusetts/02/2012 were consistently lower than those for B/
Brisbane/60/2006.
Positive correlations were also found between ELISA and HI as-
says	 (0.61	 A/California/07/2009,	 0.66	 A/Texas/50/2012,	 0.54	 B/
Brisbane/60/2009,	 0.60	 B/Massachusetts/02/2012),	 ELISA	 and	 MN	
assays	 (0.61	 A/California/07/2009,	 0.59	 A/Texas/50/2012,	 0.60	 B/
Brisbane/60/2009,	 0.51	 B/Massachusetts/02/2012),	 and	 ELISA	 and	
SRH	assays	(0.68	A/California/07/2009,	0.71	A/Texas/50/2012,	0.64	B/
Brisbane/60/2009,	0.72	B/Massachusetts/02/2012)	(Figure	2;	Table	1).
For the A strains, the correlation between HI, MN, and SRH was 
stronger than that between ELISA and the other assays. By contrast, 
F IGURE  1 Continued
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the correlation between ELISA and HI, and SRH and VN assays was 
comparable to that of the three traditional assays for the B strains.
In addition, the assay agreement on protection, as defined by 
HI	≥	40	 and	 SRH	≥	25	mm2, was evaluated using Cohen’s kappa 
statistic. The kappa statistic measures inter- rater agreement for 
categorical variables while correcting for chance. The kappa sta-
tistics	 showed	 good	 agreement	 for	 the	 A/California/07/2009	
(H1N1) (k = 0.72) and A/Texas/50/2012 (H3N2) (k	=	0.59)	influenza	
strains, indicating that most subjects were considered to be pro-
tected on the basis of both HI and SRH threshold levels. By con-
trast, the correlation for the B/Brisbane/60/2008 (k	=	0.34)	and	B/
Massachusetts/02/2012 (k	=	0.09)	 strains	was	very	 low,	especially	
for the latter. These data suggest that a high number of subjects 
are considered to be protected on the basis of the SRH protective 
threshold	 level	 but	 not	 the	 HI	 threshold.	 When	 kappa	 statistics	
were repeated, assuming an HI threshold of 20 for the B strains, 
kappa values were 0.53 for B/Brisbane/60/2008 and 0.18 for B/
Massachusetts/02/2012.
4  | DISCUSSION
The immunological response to influenza natural infection or vac-
cination is usually evaluated by serological assays such as HI, SRH, 
and MN. The HI assay is considered the gold standard as a correlate 
of protection for influenza vaccine and detects antibodies able to 
bind the viral HA and inhibit virus- red blood cells agglutination. The 
SRH assay recognizes complement activating antibodies, while the 
MN assay identifies functional neutralizing antibodies able to pre-
vent the entry or replication of the virus in mammalian cells. All three 
TABLE  1 Correlation coefficients and regression estimates
Strain Comparison X value Y value Slope Intercept
Correlation coefficient 
(r 95% CI)
A/California/7/2009	(H1N1) HI ~ MN MN HI 0.849 2.895 0.810	(0.775-	0.839)
A/Texas/50/2012 (H3N2) HI ~ MN MN HI 1.095 −0.865 0.844	(0.815-	0.869)
B/Brisbane/60/2008 (Vic) HI ~ MN MN HI 0.721 1.977 0.714	(0.665-	0.756)
B/Massachusetts/02/2012 
(Yam)
HI ~ MN MN HI 0.544 1.356 0.620	(0.560-	0.674)
A/California/7/2009	(H1N1) SRH ~ MN MN SRH 12.074 −0.657 0.855 (0.828- 0.878)
A/Texas/50/2012 (H3N2) SRH ~ MN MN SRH 9.446 −25.153 0.693	(0.642-	0.738)
B/Brisbane/60/2008 (Vic) SRH ~ MN MN SRH 9.102 11.411 0.707 (0.658- 0.750)
B/Massachusetts/02/2012 
(Yam)
SRH ~ MN MN SRH 8.953 12.958 0.672 (0.618- 0.720)
A/California/7/2009	(H1N1) SRH ~ HI HI SRH 11.465 −22.954 0.851 (0.823- 0.875)
A/Texas/50/2012 (H3N2) SRH ~ HI HI SRH 8.620 −17.660 0.821	(0.788-	0.849)
B/Brisbane/60/2008 (Vic) SRH ~ HI HI SRH 9.132 4.108 0.637	(0.579-	0.689)
B/Massachusetts/02/2012 
(Yam)
SRH ~ HI HI SRH 11.456 10.424 0.755	(0.712-	0.792)
A/California/7/2009	(H1N1) HI ~ ELISA IgG HI 0.905 −4.227 0.613 (0.552- 0.668)
A/Texas/50/2012 (H3N2) HI ~ ELISA IgG HI 0.991 −4.708 0.664	(0.609-	0.713)
B/Brisbane/60/2008 (Vic) HI ~ ELISA IgG HI 0.773 −5.463 0.544	(0.476-	0.606)
B/Massachusetts/02/2012 
(Yam)
HI ~ ELISA IgG HI 0.588 −3.371 0.604	(0.542-	0.660)
A/California/7/2009	(H1N1) MN ~ ELISA IgG MN 0.867 −5.950 0.615	(0.554-	0.670)
A/Texas/50/2012 (H3N2) MN ~ ELISA IgG MN 0.676 −0.733 0.589	(0.525-	0.646)
B/Brisbane/60/2008 (Vic) MN ~ ELISA IgG MN 0.848 −7.281 0.604	(0.542-	0.660)
B/Massachusetts/02/2012 
(Yam)
MN ~ ELISA IgG MN 0.571 −2.330 0.514	(0.443-	0.579)
A/California/7/2009	(H1N1) SRH ~ ELISA IgG SRH 13.556 −110.250 0.681	(0.629-	0.728)
A/Texas/50/2012 (H3N2) SRH ~ ELISA IgG SRH 11.148 −89.966 0.712 (0.663- 0.755)
B/Brisbane/60/2008 (Vic) SRH ~ ELISA IgG SRH 11.519 −106.559 0.637	(0.579-	0.689)
B/Massachusetts/02/2012 
(Yam)
SRH ~ ELISA IgG SRH 10.622 −76.565 0.719	(0.671-	0.761)
Correlation coefficients (Pearson’s r) and regression estimates for slope and intercept. HI, MN, and ELISA were log 2 transformed; SRH titer was used 
without transformation.
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assays are officially recognized by the EMA for the evaluation of in-
fluenza vaccine immunogenicity.1
The aim of the study was to compare the HI, SRH, MN assays, and 
ELISA	using	four	seasonal	influenza	strains	(A/California/7/2009	
(H1N1), A/Texas/50/2012 (H3N2), B/Brisbane/60/2008 Victoria 
lineage,	and	B/Massachusetts/02/2012	Yamagata	lineage).
The data highlight strong correlations between HI, MN, and SRH 
assays for influenza A strains (H1N1 and H3N2). A significant cor-
relation between HI and MN has been found by Veguilla et al27 with 
the same H1N1 strain used in this study, and, in other studies, with 
different influenza strains, such as A/Brisbane/10/2007 (H3N2), A/
Brisbane/59/2007	 (H1N1),	 and	 equine	 influenza	viruses.11,29,30,33 
Previous studies involving A strains support the strong agreement 
between HI and SRH assays found in present study.11,14,28 The 
correlation between SRH and MN assays observed in this study 
is in agreement with the findings of the previous studies that used 
equine influenza strains and H3N2 influenza strain.11,29,30 However, 
unlike	Wang	et	al,30 who found much higher correlations between 
SRH and MN assays than between SRH- HI and HI- MN assays, we 
found no significant differences among them.
F IGURE  2 Correlation between ELISA (IgG titer)- HI, ELISA (IgG titer)- MN, and ELISA (IgG titer)- SRH titers. The points are plotted in 
such a way as to show where the majority of observations are located
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The correlation among the three assays was also evaluated for 
influenza	B	strains	(Victoria	and	Yamagata	lineages),	showing	good	
agreement. These values were slightly lower than for the A strains; 
however, the difference was small. This could be due to the poor 
sensitivity	of	the	HI	assay	to	B	strains.	We	found	only	one	previ-
ous study of B strains, but this was limited to HI and SRH, which 
were applied only to the B/Beijing/1/87 strain; this found a statis-
tically significant correlation between the two assays supporting 
our data.14
Although ELISA is not officially recognized by the EMA, the 
technique is able to measure different class- specific IgM, IgA, and 
IgG antibodies. In addition, the assay is able to measure HA stalk- 
specific antibodies and could be used to evaluate the immunoge-
nicity of novel universal influenza vaccines.34 ELISA is particularly 
suitable for large- scale serological investigation, as it yields unbi-
ased results in a few hours and allows complete automation of the 
process by high- throughput testing. Our data reveal a positive cor-
relation between ELISA and the other three assays, with lower val-
ues for A strains but without differences between A and B strains. 
Only two previous studies have evaluated the correlations among 
ELISA, MN, and HI, and, in agreement with our data, have shown 
good correlations among them.31,32 The present study seems to be 
F IGURE  2 Continued
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the first to evaluate the immunological correlation between ELISA 
and SRH assay.
Until February 2017, the correlates of protection had been 
established for the HI and SRH assays only. Traditionally, an HI 
titer	≥	40	was	considered	an	immunological	correlate	of	protection	
and the best available parameter for predicting protection from 
influenza infection; a hemolysis area of 25 mm2 or greater was 
generally regarded as a protective threshold level, beyond which 
the probability of contracting influenza infection was reduced by 
50% or more.7,35 Although the traditional correlates of protection 
have been used for decades, they have been questioned. First 
of all, the correlates of protection only targeted healthy adults 
aged 18- 60 years and the over- 60s, thereby excluding children 
and other subjects at high risk. The study by Black et al36 demon-
strated	that	it	is	inappropriate	to	use	an	HI	titer	≥	40	as	a	correlate	
of protection for children under 6 years of age, as they need an 
HI titer of 110 to reach a 50% protection level. In addition, there 
was no difference between adjuvanted and non- adjuvanted vac-
cines, no defined correlates of protection specific to live attenu-
ated influenza and pandemic vaccines, and the use of the HI assay 
itself has been questioned.8,9,36-38 However, the new EMA guide-
lines1 have withdrawn the concept of the “traditional correlates 
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of	protection,”	meaning	that	an	HI	titer	≥	40	and	a	hemolysis	area	
of 25 mm2 or greater are no longer accepted as a threshold of 
seroprotection.
The data show that there is good agreement between both 
assays with regard to protection against the A strains. This means 
that subjects who are considered to be protected on the basis of 
HI threshold levels are also deemed to be protected on the basis 
of SRH threshold levels. By contrast, our comparison of correlates 
of protection for the B strains showed low and very low agree-
ment, particularly for the Massachusetts strain. Unfortunately, 
we found few previous studies that compare the correlates of pro-
tection of HI and SRH assays. Nevertheless, these studies support 
our data and reveal that SRH is more sensitive than HI in detecting 
antibodies against influenza B viruses.39,40 If the threshold level 
applied	is	reduced	from	40	to	20,	the	level	of	agreement	increases	
slightly, suggesting that the protective HI level for B strains may 
be	lower,	as	suggested	by	Hobson&Curry.2 To increase the sensi-
tivity	of	the	assay,	the	WHO	requires	that	influenza	B	viruses	be	
ether- treated for the serological diagnosis of influenza B infec-
tion; however, this treatment could reduce the specificity of the 
assay.41-43
The present study has some limitations, such as missing infor-
mation on the vaccination status of the subjects involved and the 
unavailability of paired serum samples. Another limitation is the lack 
of comparability between ether- treated B viruses and native viruses 
and between egg- grown and cell- grown viruses.
Overall, this study shows a strong positive correlation among 
the four serological assays (MN, HI, SRH, and ELISA) for both A and 
B strains; this is especially true of the HI and MN assays. However, 
it also highlights the need to further investigate the correlation be-
tween the SRH assay and ELISA. Concerning the correlates of pro-
tection,	as	defined	by	HI	≥	40	and	SRH	≥	25	mm2, we found good 
agreement regarding protection against A strains between HI and 
SRH assays, but very low agreement for the B strains, suggesting 
that SRH is more sensitive than HI in detecting antibodies against 
the influenza B viruses. As the four serological assays detect dif-
ferent sets or subsets of antibodies, combining all the assays could 
considerably improve the assessment of the immunogenicity of in-
fluenza vaccines and provide a more complete picture of antibody 
responses. In addition, it could be useful to establish the correlates 
of protection for the MN assay, in order to compare vaccine as-
sessments based on the three assays. Finally, further research on 
ELISA could be particularly useful in order to evaluate the immu-
nogenicity of novel universal influenza vaccines.
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